Sanofi launches non-profit treatments in lower income countries

The pharmaceutical company aims to bring quality medications to the worlds’ poorest countries.



Sanofi plans to produce 30 treatments to 40 lower-income countries on a non-profit basis. This is the French drugmakers' effort to increase access to medicine worldwide. The Impact brand, which is part of Sanofi’s global health unit will be providing the treatments. The Impact fund will contribute $25 million to assisting local start-up healthcare business as well as provide training on the use of the medications. Jon Fairest, the Global Head of Trade and Revenue stated, "There's a lot of noise at the moment from different companies jumping into this space... but investing in entrepreneurship, in the ecosystem, is a new thing." Early this year, Pfizer announced their intention to supply medicines and vaccines on a not-for-profit basis to 45 of the world’s low-and some lower-middle- income countries.


“The launch of the Impact brand and our Impact Fund are our latest steps to make our medicines available and to help bring quality, sustainable healthcare to people in the world’s poorest countries,” added Fairest. The treatments that will be provided are on the World Health Organization’s essential medicines list. The list includes insulin which has been singled out by the United Nations agency as a life-saving treatment for diabetics that is not as easily accessible in lower-income countries. The list contains off-patent treatments for tuberculosis, hypertension, malaria, cancer and other conditions. Details on the extent to which the prices will be brought down are still to be released. The countries involved are mainly from Africa and span from Niger to Zimbabwe. Conflict-struck countries like Syria are also part of the initiative.